CMS to Keep Covering Avastin for MBC Regardless of FDA Decision

The Centers for Medicare & Medicaid Services (CMS) plans to keep covering Genentech’s Avastin for metastatic breast cancer (MBC) despite an FDA appeal panel’s recommendation to axe the indication, and an upcoming FDA decision that could strip the indication from the drug’s label.
Drug Industry Daily